USANA Health Sciences (NYSE:USNA) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a buy rating in a report published on Saturday.

A number of other research firms also recently weighed in on USNA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, USANA Health Sciences currently has an average rating of “Reduce” and an average price target of $36.00.

USANA Health Sciences Price Performance

NYSE:USNA opened at $21.69 on Friday. The stock has a market cap of $396.46 million, a PE ratio of 39.43, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. USANA Health Sciences has a fifty-two week low of $18.48 and a fifty-two week high of $38.32. The stock’s 50-day moving average is $20.71 and its two-hundred day moving average is $23.49.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The business had revenue of $226.20 million during the quarter, compared to analyst estimates of $225.96 million. On average, equities research analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. National Bank of Canada FI lifted its holdings in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the period. Parallel Advisors LLC lifted its stake in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after buying an additional 3,589 shares during the last quarter. CWM LLC boosted its holdings in shares of USANA Health Sciences by 109.7% during the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after buying an additional 1,445 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after buying an additional 1,327 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.